Furthermore, cardiac-specific inhibition of CaMKK2 worsens cardiac hypertrophy induced by transverse aortic binding accompanied by reduced AMPK and PGC-1α levels and mitochondrial biogenesis (Watanabe et al, 2014). This evidence concerns the gene PPARGC1A and cardiac hypertrophy.